PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Latest Episodes:

Benjamin M. Brucker, MD - Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists Jun 29, 2023

Show notes

Go online to PeerView.com/QGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities. This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety. Upon completion of this activity, participants should be better able to: Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities; Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB; Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology; and Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns.

Elena Elimova, MD, M.Sc., FRcPC - Polishing Management Protocols in HER2-Expressing GI Cancers With Targeted Agents: A Focus on Refining Team-Based Strategies to Individualize BTC and GEA Care Jun 28, 2023

Show notes

Go online to PeerView.com/NXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy based on molecular findings. In this activity, our expert faculty will provide updates on evolving evidence-based practice standards and discuss how to effectively integrate the latest treatment advances into practice. You will learn to identify appropriate baseline diagnostic testing to inform the selection of targeted therapy for your patients with gastrointestinal cancers. Our experts will also introduce the latest evidence supporting relevant, novel strategies and explain when to initiate these agents in comparison with conventional treatment. Upon completion of this activity, participants should be better able to: Recognize current evidence supporting molecular testing, including HER2 expression, and its role in treatment selection for patients with HER2-positive GI cancers; Implement personalized treatment strategies based on molecular findings, current evidence and recommendations, and patient-specific factors when managing HER2-expressing GI cancers; and Apply practical strategies to manage and mitigate treatment-related AEs associated with HER2-targeting agents when managing BTC and GEA.

Luke Maese, DO, Rachel Rau, MD - Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy Jun 27, 2023

Show notes

Go online to PeerView.com/TAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibodies, tyrosine kinase inhibitors, cellular therapy, and modern asparaginases, such as pegylated Escherichia coli and Erwinia chrysanthemi compounds have vastly improved treatment plans for pediatric and adolescent and young adult (AYA) populations with acute lymphoblastic leukemia (ALL). The approval of newer Erwinia formulations has expanded the therapeutic foundation on which clinicians can build effective strategies to address challenges such as asparaginase discontinuation due to hypersensitivity or silent inactivation. This "Clinical Consults" activity focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric and AYA ALL therapy. Watch experts provide guidance on the modern use of asparaginase therapy and share tactics for addressing real-world barriers to effective care, including hypersensitivity, silent inactivation, and asparaginase discontinuation, and get their perspectives on optimized asparaginase dosing and toxicity mitigation approaches. Learn how you can utilize modern asparaginase strategies to improve outcomes in ALL by watching today! Upon completion of this activity, participants should be better able to: Discuss current efficacy evidence and unmet needs related to the optimized use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds; Devise strategies to address therapeutically relevant considerations related to asparaginase use for pediatric ALL such as appropriate dosing, pre-empting truncation/discontinuation, and drug-related toxicity; Identify the emergence of asparaginase hypersensitivity, silent inactivation, or toxicity through the use of evidence-based monitoring plans in pediatric ALL; and Select treatment strategies to avoid asparaginase discontinuation and ensure adequate exposure to therapy, including switching to Erwinia asparaginase options after confirming hypersensitivity.

Jaime Almandoz, MD, MBA, FTOS - Practicing What We Preach: Your Role as an Obesity Medicine Specialist, Inspiring Change, and Overcoming Negative Weight Biases to Prioritize the Management of Obesity as a Chronic Disease Jun 20, 2023

Show notes

Go online to PeerView.com/QFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging activity, which is based on a pre-conference workshop held at OMA 2023, experts in obesity management aim to change misperceptions about obesity and explain best practices for treating this chronic condition, which include the importance of anti-obesity medications (AOMs) in achieving individualized weight goals and improving overall health outcomes by reducing the risk and progression of obesity-related comorbidities. Upon completion of this activity, participants should be better able to: Initiate appropriate, unbiased, and nonjudgmental conversations with patients about obesity acknowledging it as a chronic, treatable disease rather than a result of personal irresponsibility; Compare the efficacy and safety profiles of current and emerging anti-obesity medications and their potential to support weight loss efforts and minimize the impact of obesity-related comorbidities; and Employ shared decision-making to implement a comprehensive, individualized treatment plan that incorporates appropriate use of long-term anti-obesity medications to achieve and maintain realistic weight loss in people with obesity.

Miguel Regueiro, MD - Taking Fuel From the IBD Fire: Applying New Evidence on Sphingosine-1-Phosphate Receptor Modulation as an Effective Oral Option for Management of Ulcerative Colitis Jun 01, 2023

Show notes

Go online to PeerView.com/FNG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Much progress has been made in defining the genetic abnormalities and associated abnormal pathophysiology underlying the spontaneous and chronic inflammation that characterizes inflammatory bowel disease (IBD). Medications that suppress or modify immune activity form the core of effective treatment for IBD. Sphingosine-1-phosphate (S1P) receptor modulators, a small-molecule therapeutic option, provide a target-specific approach with a favorable safety profile. Multiple S1P receptor modulators are in development, and ozanimod became the first agent in this class to receive FDA approval for the treatment of moderately to severely active ulcerative colitis in 2021. In this activity, based on a recent live symposium, expert faculty will discuss the therapeutic effects of S1P receptor modulators on the underlying pathophysiology of IBD and identify patients with UC who could benefit from treatment with these agents. In addition, the faculty will discuss individualizing treatment using S1P receptor modulators for appropriate patients with IBD in accordance with current evidence and guidelines. Upon completion of this activity, participants should be better able to: Explain how the therapeutic effects of sphingosine-1-phosphate (S1P) receptor modulators address the underlying pathophysiology of IBD; Identify patients with UC who could benefit from the use of therapy with S1P receptor modulators; and Individualize treatment using S1P receptor modulators for appropriate patients with UC in accordance with current evidence and guidelines

Anna Chodos, MD, MPH - Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care Jun 01, 2023

Show notes

Go online to PeerView.com/XUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process. Upon completion of this activity, participants should be better able to: Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD; Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns; and Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results

Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Leading Change, Leading Advances in CLL Care: Guidance on Delivering Modern Targeted and Cellular Therapeutics Jun 01, 2023

Show notes

Go online to PeerView.com/AZG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you updated on the leading advances in CLL care and the role nurses play in ensuring the best outcomes for patients? Find out in this PeerView Nurse MasterClass, where a panel of leading CLL hematology-oncology nurse experts present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTKi as well as BCL2i. Our experts will also present a rich collection of case examples from nursing practice designed to explore how nurses can be the cornerstone of the management team. This event recorded at the annual ONS Congress was developed in collaboration with the CLL Society and will also feature a patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey. Get updated on the advances in CLL care and earn NCPD/ILNA credit today! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence and guidelines supporting the use of established and emerging targeted and cellular therapies for the management of patients with CLL across several lines of therapy; Implement nursing protocols to optimize the integration of targeted and cellular therapies into personalized management plans for patients with CLL, including via a clinical trial; Provide counseling to patients with CLL on their disease prognosis, differences among agent classes, therapeutic expectations, dosing, and safety considerations; and Address core practical considerations associated with the use of targeted and cellular therapies, such as dosing, scheduling, care coordination, monitoring, and treatment-emergent adverse events

Nicholas K. Mollanazar, MD, MBA - Targeting Disease Pathophysiology to Achieve Effective Treatment in Prurigo Nodularis Jun 01, 2023

Show notes

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don’t forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, Zahra Mahmoudjafari, PharmD, MBA, BCOP - Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy Jun 01, 2023

Show notes

Go online to PeerView.com/NDY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM! Upon completion of this activity, participants should be better able to: Describe the mechanisms of action, dosing, efficacy evidence, and safety evidence supporting the treatment roles of antibody-based and CAR-T therapies in multiple myeloma (MM), including CD38 and BCMA-directed agents; Implement pharmacist-guided strategies to promote optimal clinical integration of established and emerging antibody and cellular therapies across the spectrum of MM; and Develop modernized patient-, staff-, and institution-directed protocols to address practical aspects of care when using antibody and cellular therapy platforms, including dosing, safety, patient and staff counseling, and managing supportive therapies

Monica Tang, MD - Pulling the Plug on Severe Asthma: Taking a Closer Look at an Underrecognized Biomarker to Assess Disease Severity and Tailor Treatment Jun 01, 2023

Show notes

Go online to PeerView.com/SGZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mucus plugging contributes to airway obstruction and death in acute asthma and is increasingly being recognized as a significant contributory factor to persistent, severe asthma. Pulmonologists, allergy and immunology specialists, and other healthcare professionals need to be aware of these latest insights into the pathophysiology of severe asthma to optimally care for their patients. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Dr. Monica Tang will show learners how to identify the presence of airway mucus plugging on HRCT, and she will review the latest evidence with regard to mucus plugging treatment. Upon completion of this activity, participants should be better able to: Explain the role of mucus plugging as a contributory factor to airway obstruction and symptoms in severe asthma and its implications for treatment; Identify the presence of airway mucus plugging on HRCT according to current expert recommendations; and Apply recent insights into the role of mucus plugging, as well as the latest clinical evidence, to the selection of treatment for patients with severe asthma